Investor Presentation - Ebola Clinical Program

• Island Pharmaceuticals is advancing Galidesivir as a multi-filovirus countermeasure.
• Galidesivir shows promising efficacy in both Marburg and Ebola NHP models.
• Government-approved deployment of Galidesivir in Uganda under WHO MEURI framework.

Island Pharmaceuticals is focusing on Galidesivir as a multi-filovirus countermeasure, addressing the urgent need for broad-spectrum antivirals. The company has secured government approvals to deploy Galidesivir in Uganda under the WHO MEURI framework, enabling the collection of real-world clinical data during the Bundibugyo Ebola outbreak. Galidesivir has demonstrated significant efficacy in both Marburg and Ebola NHP models, with high survival rates when treatment is initiated post-infection. This deployment provides a unique opportunity to generate prospective human data in the intended disease setting, complementing the FDA Animal Rule program and strengthening Galidesivir's development strategy.